1800 202 8726
Insurance claims

Why Biopsy Insurance Claims — Get Rejected

A rejected biopsy claim is almost always fixable. The most common grounds — no pre-authorisation, a lab not on the panel, or a missing histopathology report — are problems you can resolve with the right documents.

Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed September 2026

  • Most rejections are preventable — The three most common grounds are missed before submission, not discovered at assessment.
  • Add-ons are the hidden cost — IHC and molecular tests can exceed the biopsy itself, and are where insurers push back hardest.
  • You have the right to appeal — Every insurer in India must have a grievance process. If that fails, the Insurance Ombudsman is the next step.
  • Act within the window — Most policies allow 15 to 30 days to file an appeal. Missing that deadline can close the door permanently.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Get an indicative cost estimate

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

Biopsy claims are most often rejected because the procedure was not pre-authorised, the lab is not on the insurer's approved panel, or the histopathology add-ons were coded differently from the main procedure. All three are preventable. The checklist below tells you what to check before you submit.

What does a biopsy cost, and which parts do insurers push back on?

Procedure or componentIndicative cost (India, 2026)Common insurer position
Fine needle aspiration cytology (FNAC)₹500 – ₹1,500Often coded as OPD — may not be claimable under inpatient-only policies
USG-guided core needle biopsy₹3,000 – ₹8,000Usually covered if pre-authorisation was obtained before the procedure
Surgical or excision biopsy₹15,000 – ₹50,000Usually covered as a daycare or short-stay procedure with prior auth
Histopathology processing₹1,500 – ₹4,000Covered under some policies; excluded or under-reimbursed under others
Immunohistochemistry (IHC), per marker₹2,000 – ₹5,000Frequently queried — requires written clinical justification for each marker
Molecular or genomic panel (NGS, FISH)₹20,000 – ₹80,000Excluded by most standard policies; some critical illness or top-up plans may cover it

What to check before you submit the claim

  • Confirm pre-authorisation was obtained before the procedure, not after.
  • Verify the laboratory is on your insurer's empanelled list before the sample is sent.
  • Collect the histopathology report — a discharge summary alone is not enough.
  • Ask your oncologist for a written referral or clinical indication letter linking the biopsy to the suspected diagnosis.
  • Check that the procedure codes on the hospital bill match what was pre-authorised.
  • List IHC and molecular tests as separate line items with individual justification, not bundled under the biopsy fee.
  • Confirm whether your policy classifies the procedure as OPD or inpatient — FNAC in particular is often OPD.
  • Note the claim submission deadline in your policy document and file well before it.

What will this actually cost you?

Costs depend on the regimen, the number of cycles and your scheme eligibility. Send your reports and we will give you an itemised, indicative estimate.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Know the cost before you commit

An itemised estimate, plus a check of which schemes you may qualify for.

Book Free Consultation Call 1800 202 8726

Why do insurers say a cancer biopsy was not medically necessary?

This is one of the most distressing rejections, because from your family's perspective the biopsy was the only way to know whether cancer was present. Insurers apply the phrase differently: they may argue that a less expensive test should have been done first, or that the specific technique was not the standard of care for that tumour site.

The strongest response to this rejection is a letter from your oncologist explaining, in clinical terms, why the biopsy was the appropriate next step — not a general statement, but a specific explanation tied to your imaging findings and clinical presentation at that point.

If the rejection cites a particular guideline, ask your oncologist whether NCCN, ESMO, or ICMR guidance supports the procedure for your cancer type. A written response that cites the applicable guideline by name carries more weight with an insurer than a general appeal.

How to appeal a rejected biopsy claim

  1. Get the rejection in writing with the specific ground stated

    Ask the insurer for the rejection letter naming the exact reason. Vague language like 'not payable as per policy' is not sufficient — you are entitled to a clear, specific explanation.

  2. Match the rejection ground to the document it requires

    Each rejection reason points to a specific gap: no pre-auth needs the referral trail and booking record; wrong lab needs panel-approval clarification; not medically necessary needs your oncologist's clinical justification letter.

  3. Ask your oncologist for a medical necessity letter

    The letter should state why the biopsy was clinically indicated, what the decision was based on, and which guidelines supported it. A letter that addresses the insurer's stated ground directly is more effective than a general one.

  4. Submit the appeal within the grievance window

    Most policies allow 15 to 30 days from the date of rejection — check your policy document for the exact period. Submit by registered post or through the insurer's online portal, and keep copies of everything you send and every acknowledgment you receive.

  5. Escalate to the Insurance Ombudsman if the internal appeal fails

    If your insurer's own grievance process does not resolve the matter, you can file a complaint with the Insurance Ombudsman for your region at no cost. IRDAI's Bima Bharosa portal also accepts online complaints. The Ombudsman's ruling is binding on the insurer.

Explore 71 more Understanding Your Biopsy and Whether You Need One topics

HUB — Does a Biopsy Spread Cancer? Myths and Evidence

HUB — What Is a Biopsy? Everything You Need to Know

All Understanding Your Biopsy and Whether You Need One →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

What are the most common reasons insurers reject biopsy claims?

The most common grounds are: the procedure was not pre-authorised; the laboratory is not on the insurer's empanelled panel; the histopathology report or clinical referral letter is missing from the submission; the procedure is classified as OPD when the policy covers only inpatient treatment; or the add-on tests — IHC, molecular panels — are bundled rather than itemised separately. Each of these is fixable before submission or during appeal, once you know which specific ground applies to your rejection.

Does my insurer need to pre-authorise a biopsy before it happens?

For surgical and USG-guided core needle biopsies, most group and individual health policies in India require pre-authorisation before the procedure takes place. FNAC is more often classified as an OPD procedure and may not need pre-auth — but it may also not be covered under an inpatient-only policy. The safest step is to call your insurer's cashless helpline before any biopsy and ask explicitly. Getting written confirmation of pre-auth, even for a procedure you expect to be covered, removes the single most common rejection ground.

What if the lab my doctor sent the sample to is not on the approved panel?

This happens often when a specialist centre sends tissue to a reference pathology laboratory for IHC or molecular testing. The immediate step is to ask the insurer whether the laboratory can be approved retrospectively, or whether a reimbursement route exists for out-of-panel labs with prior written approval. For future claims, ask your oncologist's team to confirm which reference labs are empanelled with your insurer before the biopsy is done — swapping labs after the sample has been processed is almost never possible.

Can IHC stains and molecular tests be claimed separately from the biopsy?

They can, but they must appear as separate line items with individual clinical justification on the bill, not bundled into the histopathology fee. Many rejections happen because IHC is invoiced as part of a single pathology charge, and the insurer treats the entire bundle as one non-pre-authorised item. A clear itemised bill — each test listed separately with your oncologist's written explanation of why each was clinically required — significantly improves the chance of reimbursement. Whether your specific policy covers these tests at all is a separate question; check the inclusions and exclusions schedule in your policy document.

How long do I have to appeal, and what is the process?

Most policies set a window of 15 to 30 days from the date of rejection to file a formal grievance. Check your policy document for the exact period — missing it can make the rejection final. Submit your appeal in writing, attach all supporting documents, and keep copies of every page you send and every acknowledgment you receive. The insurer must respond to a registered complaint within the timeframe IRDAI prescribes. If they do not respond or if the response is unsatisfactory, that record of the attempt supports your Ombudsman complaint.

What if the insurer rejects my appeal as well?

You have two routes. The first is the Insurance Ombudsman for your region — a free statutory service that handles claims disputes up to a prescribed ceiling, with rulings that are binding on the insurer. The second is IRDAI's Bima Bharosa integrated grievance portal, where you can file online if the insurer has not resolved your complaint within 30 days of registration. For very large claims — comprehensive molecular panels and complex surgical biopsies can reach significant amounts — a lawyer who handles insurance disputes is worth consulting before you reach the Ombudsman stage.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation